RHBDD1 Inhibitors
RHBDD1 inhibitors are a class of chemical compounds designed to specifically target and inhibit the activity of RHBDD1, a rhomboid protease. RHBDD1 is part of the broader family of intramembrane serine proteases known as rhomboid proteins, which are involved in cleaving substrates within the lipid bilayer of cellular membranes. These proteases play critical roles in regulating various cellular processes, including signal transduction, protein trafficking, and the maintenance of cellular homeostasis. RHBDD1, in particular, is known for its involvement in protein quality control and the regulation of membrane-bound proteins, making it an important modulator of cell function. Inhibitors of RHBDD1 work by blocking its proteolytic activity, thereby preventing it from cleaving its substrate proteins. This leads to alterations in the processing and regulation of specific membrane-associated proteins.
The inhibition of RHBDD1 can have a profound impact on cellular pathways that depend on its proteolytic function. By preventing RHBDD1 from cleaving its substrates, these inhibitors can disrupt protein maturation, trafficking, and signaling processes that rely on precise protease-mediated regulation. Researchers use RHBDD1 inhibitors to study the specific roles that this protease plays in cellular dynamics, particularly in relation to the management of membrane-bound proteins. These inhibitors help scientists explore the molecular mechanisms that govern intramembrane proteolysis and how dysregulation of this process affects cell behavior. Additionally, RHBDD1 inhibitors offer insight into the broader family of rhomboid proteases, revealing the diverse roles these proteases play across different biological systems. Understanding the function of RHBDD1 through inhibition provides valuable knowledge about its contribution to cellular homeostasis, signal transduction, and protein turnover, allowing researchers to map out the intricate networks that regulate membrane protein activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 is a potent and selective inhibitor of the proteasome, which is responsible for the degradation of proteins. It irreversibly binds to the active site of the proteasome, preventing its function and leading to the accumulation of ubiquitinated proteins. By inhibiting the proteasome, MG-132 can disrupt the degradation of RHBDD1 and potentially lead to its accumulation, thereby inhibiting its activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a reversible inhibitor of the proteasome. It binds to the catalytic site of the proteasome and inhibits its activity, leading to the accumulation of ubiquitinated proteins. By inhibiting the proteasome, bortezomib can disrupt the degradation of RHBDD1 and potentially lead to its accumulation, thereby inhibiting its activity. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Epoxomicin is a potent and irreversible inhibitor of the proteasome. It binds to the active site of the proteasome and inhibits its function, leading to the accumulation of ubiquitinated proteins. By inhibiting the proteasome, epoxomicin can disrupt the degradation of RHBDD1 and potentially lead to its accumulation, thereby inhibiting its activity. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Lactacystin is a reversible inhibitor of the proteasome. It binds to the catalytic site of the proteasome and inhibits its activity, leading to the accumulation of ubiquitinated proteins. By inhibiting the proteasome, lactacystin can disrupt the degradation of RHBDD1 and potentially lead to its accumulation, thereby inhibiting its activity. | ||||||
Calpeptin | 117591-20-5 | sc-202516 sc-202516A | 10 mg 50 mg | $121.00 $456.00 | 28 | |
Calpeptin is a reversible inhibitor of calpains, a family of calcium-dependent cysteine proteases. It inhibits the activity of calpains, which are involved in the degradation of proteins. By inhibiting calpains, calpeptin can potentially prevent the degradation of RHBDD1 and inhibit its activity. | ||||||
E-64 | 66701-25-5 | sc-201276 sc-201276A sc-201276B | 5 mg 25 mg 250 mg | $281.00 $947.00 $1574.00 | 14 | |
E-64 is a reversible inhibitor of cysteine proteases, including cathepsins. It irreversibly binds to the active site of cysteine proteases, preventing their activity. By inhibiting cysteine proteases, E-64 can potentially prevent the degradation of RHBDD1 and inhibit its activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a selective inhibitor of p38 MAPK, a kinase involved in various cellular processes, including inflammation and stress responses. By inhibiting p38 MAPK, SB 203580 can indirectly inhibit RHBDD1, which may be regulated by this kinase. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a potent and selective inhibitor of PI3K, a kinase involved in cell survival and proliferation pathways. By inhibiting PI3K, LY 294002 can indirectly inhibit RHBDD1, which may be regulated by PI3K signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a selective inhibitor of MEK1, a kinase involved in the MAPK/ERK signaling pathway. It inhibits the phosphorylation of ERK1/2, thereby blocking the activation of downstream targets. By inhibiting the MAPK/ERK pathway, PD98059 can indirectly inhibit RHBDD1, which is involved in this signaling pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a selective inhibitor of JNK, a kinase involved in stress responses and apoptosis. By inhibiting JNK, SP600125 can indirectly inhibit RHBDD1, which may be regulated by JNK signaling. | ||||||